Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Amgen (NasdaqGS:AMGN) recently faced a legal setback, with a U.S. District Court jury finding the company liable for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% from ...

In February 2025, Regeneron initiated a quarterly cash dividend program and declared a dividend of $0.88 per share. The board also authorized an additional $3.0 billion share repurchase program ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...

Explore Regeneron Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for REGN. Sanofi plans $20 billion US investment by 2030 to expand R&D and ...

Then I take a look at the company’s new dividend and buyback strategy, and how that gives me confidence in Regeneron’s long-term cash flow capabilities. In Q4 of 2024, Regeneron reported $1.5B ...

Regeneron Q1 EPS fell 14% to $8.22 ... Don’t miss this list of 10 overlooked stocks—including one paying a 9% dividend—before Wall Street catches on. The company reported sales of $3. ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...